Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386987 | 0.91 | ALDH1A1 (0.34) | ALDH1A1PTGDR2FPR2PROKR1CCR3 | |
| SCHEMBL13308228 | 0.91 | MC4R (0.34) | ALDH1A1RAB9ALMNAGLASMN1; SMN2 | |
| SCHEMBL3387358 | 0.87 | ALDH1A1 (0.37) | ALDH1A1RAB9ALMNACDK9FPR2 | |
| SCHEMBL3355555 | 0.86 | CCR1 (0.34) | ALDH1A1RAB9ALMNASMN1; SMN2FPR2 | |
| SCHEMBL3353490 | 0.86 | MC4R (0.34) | ALDH1A1PTGDR2FPR2PROKR1MGLL | |
| SCHEMBL3381860 | 0.86 | ALDH1A1 (0.37) | ALDH1A1RAB9AFPR2PROKR1 | |
| SCHEMBL3355415 | 0.84 | ALDH1A1 (0.35) | ALDH1A1RAB9ALMNAGLASMN1; SMN2 | |
| SCHEMBL3354423 | 0.84 | LMNA (0.37) | ALDH1A1LMNASMN1; SMN2FPR2PROKR1 | |
| SCHEMBL3354045 | 0.84 | ALDH1A1 (0.34) | ALDH1A1LMNACDK9MGLL | |
| SCHEMBL3355857 | 0.83 | MC4R (0.34) | ALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | ALDH1A1 903/4885RAB9A 4434/4885LMNA 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.